Compare CVS Health Corp (CVS) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Northrop Grumman Corporation — how do they compare? CVS Health Corp trades at $104.91 (market cap $135.48B), while Northrop Grumman Corporation trades at $525.51 (market cap $75.09B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | NOC | |
|---|---|---|
Market Cap | $135.48B | $75.09B |
Sector | Health | Industrials |
52-Week High | $106.18 | $768.02 |
52-Week Low | $58.75 | $496.02 |
Enterprise Value | $202.02B | $89.31B |
Dividend Yield | 2.51% | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Northrop Grumman (NOC) trades at $541.82, up 0.41% with neutral technical signals. The company shows strong fundamentals with consistent earnings beats, a 10.8% net income margin, and a $96 billion backlog supporting growth. Recent news highlights expansion in defense and aerospace sectors, driven by increased government spending and new contracts.
Outlook is positive with a consensus price target of $655, indicating 21% upside. Risks include political budget shifts and execution challenges. Analyst sentiment is bullish (57% buy ratings), but investors should monitor Q2 2026 earnings due July 21 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
